Effectiveness of bevacizumab in the treatment of metastatic colorectal cancer: a systematic review and meta-analysis

被引：0
|
作者：
Yu Song
Qianqian Mao
Manling Zhou
Cheng-Jiang Liu
Li Kong
Ting Hu
机构：
[1] the First Affiliated Hospital of Shandong Traditional Medical University,Department of Intensive Care Unit
[2] Zhongda Hospital,Department of Oncology, School of Medicine
[3] Southeast University,Department of Oncology
[4] Shenzhen Longhua District Central Hospital,Department of General Medicine
[5] Affiliated Anqing First People’s Hospital of Anhui Medical University,Department of General Practice
[6] Anqing Municipal Hospital,undefined
来源：
BMC Gastroenterology | / 24卷
关键词：
Bevacizumab; Colorectal cancer; Odds ratio; Combination;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Effectiveness of bevacizumab in the treatment of metastatic colorectal cancer: a systematic review and meta-analysis
    Song, Yu
    Mao, Qianqian
    Zhou, Manling
    Liu, Cheng-Jiang
    Kong, Li
    Hu, Ting
    BMC GASTROENTEROLOGY, 2024, 24 (01)
  • [2] The effectiveness and safety of bevacizumab versus cetuximab in the treatment of colorectal cancer: a systematic review and meta-analysis
    Yuying Cui
    Yingxue Guo
    International Journal of Clinical Pharmacy, 2022, 44 : 843 - 851
  • [3] The effectiveness and safety of bevacizumab versus cetuximab in the treatment of colorectal cancer: a systematic review and meta-analysis
    Cui, Yuying
    Guo, Yingxue
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2022, 44 (04) : 843 - 851
  • [4] Bevacizumab and erlotinib versus bevacizumab for colorectal cancer treatment: systematic review and meta-analysis
    Kaveh, Sara
    Ebrahimi, Parvin
    Rezapour, Aziz
    Mozafari, Masoud
    Sayehmiri, Kourosh
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (01) : 30 - 41
  • [5] Bevacizumab and erlotinib versus bevacizumab for colorectal cancer treatment: systematic review and meta-analysis
    Sara Kaveh
    Parvin Ebrahimi
    Aziz Rezapour
    Masoud Mozafari
    Kourosh Sayehmiri
    International Journal of Clinical Pharmacy, 2019, 41 : 30 - 41
  • [6] Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis
    Baraniskin, Alexander
    Buchberger, Barbara
    Pox, Christian
    Graeven, Ulli
    Holch, Julian W.
    Schmiegel, Wolff
    Heinemann, Volker
    EUROPEAN JOURNAL OF CANCER, 2019, 106 : 37 - 44
  • [7] Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysis
    Rosa, Bruno
    de Jesus, Jose Paulo
    de Mello, Eduardo L.
    Cesar, Daniel
    Correia, Mauro M.
    ECANCERMEDICALSCIENCE, 2015, 9
  • [8] Publisher Correction to: The effectiveness and safety of bevacizumab versus cetuximab in the treatment of colorectal cancer: a systematic review and meta-analysis
    Yuying Cui
    Yingxue Guo
    International Journal of Clinical Pharmacy, 2022, 44 : 1572 - 1572
  • [9] Trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer: results of a systematic review and meta-analysis
    Yoshino, Takayuki
    Taieb, Julien
    Kuboki, Yasutoshi
    Pfeiffer, Per
    Kumar, Amit
    Hochster, Howard S. S.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [10] Efficacy and safety of bevacizumab in elderly or unfit patients with metastatic colorectal cancer: A systematic review and meta-analysis
    Antonuzzo, Lorenzo
    Aprile, Giuseppe
    Barni, Sandro
    Maiello, Evaristo
    Masi, Gianluca
    Petrelli, Fausto
    Scartozzi, Mario
    Torri, Valter
    Pinto, Carmine
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345